Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04375956 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients(MITO 27) | unknown | Phase 2 | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05160285 | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma | unknown | Phase 2 | 29 | YULISUOTHER | 1 | Dec 16, 2021 |
| clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT04839510 | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | unknown | Phase 2 | 58 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05156424 | A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Kira MurphyOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05156450 | TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 30 | West China HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05151549 | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05121363 | A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma | unknown | Phase 2 | 113 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05137171 | AK105 Combined With Anlotinib in Patients With Cervical Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Nov 30, 2021 | clinicaltrials |
| NCT02689167 | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma(SURF) | unknown | Phase 2 | 226 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05124431 | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma(ALTER-UC-001) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | unknown | Phase 2 / Phase 3 | 469 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04379362 | MRI-guided Focal Laser Ablation(Unicorn) | unknown | Phase 2 | 53 | Radboud University Medical CenterOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01444807 | Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases | unknown | Phase 2 | 132 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04534998 | Robotic-assisted vs. Open Partial Nephrectomy(ROBOCOP) | unknown | Phase 2 | 50 | Universitätsmedizin MannheimOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03305224 | The Combination Therapy With Ra-223 and Enzalutamide(CORE-OCU) | unknown | Phase 2 | 10 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT04217798 | Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Peking Union Medical College HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT05030077 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | unknown | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03462212 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination(MITO25) | unknown | Phase 1 / Phase 2 | 290 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04238988 | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer(MITO CERV 3) | unknown | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT03040791 | Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)(ImmunoProst) | unknown | Phase 2 | 38 | Hospital Moinhos de VentoOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT05016973 | A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer | unknown | Phase 2 | 25 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT03050866 | Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)(CABA-V7) | unknown | Phase 2 | 140 | Erasmus Medical CenterOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT05001763 | Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy | unknown | Phase 2 | 160 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04887961 | Reprab Study: PLD + Trabectedin Rechallenge(MITO36) | unknown | Phase 2 | 64 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04995016 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma(PANDORA) | unknown | Phase 2 | 18 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04985110 | Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital | unknown | Phase 2 | 78 | Indonesia UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04973904 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04734665 | Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor(NIRVANA-R) | unknown | Phase 2 | 44 | Yonsei UniversityOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT04958473 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer(SAARCC) | unknown | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT04926155 | The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 234 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT04922047 | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)(TACBIN-01) | unknown | Phase 1 / Phase 2 | 6 | RenJi HospitalOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04918628 | Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer(CRTCP) | unknown | Phase 2 | 50 | Taizhou HospitalOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04836663 | A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors | unknown | Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04395612 | Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer(CQGOG0101) | unknown | Phase 2 | 38 | Chongqing University Cancer HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04556539 | Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | unknown | Phase 2 | 104 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 12, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT00703105 | Ovarian Dendritic Cell Vaccine Trial | unknown | Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04361370 | Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer(OPEB-01) | unknown | Phase 2 | 44 | Yonsei UniversityOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04828616 | Study of DP303c Injection in Patients With Advanced Ovarian Cancer | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 20, 2021source: clinicaltrials